Literature DB >> 35538262

Bortezomib-induced cardiogenic shock in a multiple myeloma patient with K light-chain cardiac amyloidosis.

Valentino Dammassa1,2, Alessandra Greco3, Rossana Totaro3, Costanza Natalia Julia Colombo4, Claudia Raineri5, Rita Camporotondo3, Gaetano Maria De Ferrari5,6, Francesco Mojoli4,7, Eloisa Arbustini8, Luigi Oltrona Visconti3, Guido Tavazzi4,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35538262     DOI： 10.1007/s00277-022-04858-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   4.030


× No keyword cloud information.
  3 in total

Review 1.  Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.

Authors:  Margarita Bockorny; Saneka Chakravarty; Peter Schulman; Bruno Bockorny; Robert Bona
Journal:  Acta Haematol       Date:  2012-09-04       Impact factor: 2.195

Review 2.  Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.

Authors:  Daniel C Cole; William H Frishman
Journal:  Cardiol Rev       Date:  2018 May/Jun       Impact factor: 2.644

3.  Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy.

Authors:  Marcelle G Meseeha; Victor O Kolade; Maximos N Attia
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.